Terence M. Doherty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Terence M. Doherty has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey N. Hendy
Metabolic Disorders and Complications, McGill University Health Centre-Research Institute, Departments of Medicine, Physiology, and Human Genetics, McGill University, Montreal, QC H4A 3J1, Canada
1 shared publication - Joaquín Madrenas
The Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center
1 shared publication - John Kenneth McCormick
Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1, Canada
1 shared publication - Joseph J. Zeppa
Division of Medical Microbiology, Department of Laboratory Medicine and Pathobiology, University of Toronto
1 shared publication Mark A Hancock
Surface Plasmon Resonance-Mass Spectrometry Facility, McGill University, Montreal, Quebec H3G 1Y6, Canada
1 shared publication- Zhigang Li
Microbiome and Disease Tolerance Centre, Department of Microbiology and Immunology, McGill University, Montreal, Quebec H3A 2B4, Canada; and
1 shared publication
Latest Publications
- 15 February 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (4) , 1471-1479
Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells
Canonical Ag-dependent TCR signaling relies on activation of the src-family tyrosine kinase LCK. However, staphylococcal superantigens can trigger TCR signaling by activating an alternative pathway that is independent of LCK and utilizes a Gα11-containing G protein–coupled receptor (GPCR) leading to PLCβ activation. The molecules linking the superantigen to GPCR signaling are unknown. Using the ligand-receptor capture technology LRC-TriCEPS, we identified LAMA2, the α2 subunit of the extracellular matrix protein laminin, as the coreceptor for staphylococcal superantigens. Complementary binding assays (ELISA, pull-downs, and surface plasmon resonance) provided direct evidence of the interaction between staphylococcal enterotoxin E and LAMA2. Through its G4 domain, LAMA2 mediated the LCK-independent T cell activation by these toxins. Such a coreceptor role of LAMA2 involved a GPCR of the calcium-sensing receptor type because the selective antagonist NPS 2143 inhibited superantigen-induced T cell activation in vitro and delayed the effects of toxic shock syndrome in vivo. Collectively, our data identify LAMA2 as a target of antagonists of staphylococcal superantigens to treat toxic shock syndrome.
- 15 February 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (4) , 1471-1479
Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells
Canonical Ag-dependent TCR signaling relies on activation of the src-family tyrosine kinase LCK. However, staphylococcal superantigens can trigger TCR signaling by activating an alternative pathway that is independent of LCK and utilizes a Gα11-containing G protein–coupled receptor (GPCR) leading to PLCβ activation. The molecules linking the superantigen to GPCR signaling are unknown. Using the ligand-receptor capture technology LRC-TriCEPS, we identified LAMA2, the α2 subunit of the extracellular matrix protein laminin, as the coreceptor for staphylococcal superantigens. Complementary binding assays (ELISA, pull-downs, and surface plasmon resonance) provided direct evidence of the interaction between staphylococcal enterotoxin E and LAMA2. Through its G4 domain, LAMA2 mediated the LCK-independent T cell activation by these toxins. Such a coreceptor role of LAMA2 involved a GPCR of the calcium-sensing receptor type because the selective antagonist NPS 2143 inhibited superantigen-induced T cell activation in vitro and delayed the effects of toxic shock syndrome in vivo. Collectively, our data identify LAMA2 as a target of antagonists of staphylococcal superantigens to treat toxic shock syndrome.